Marketing: Page 3

  • Akili's digital therapeutic, EndeavorRx, involves navigating obstacles in different courses. It's intended to improve attention.
    Image attribution tooltip
    Courtesy of Akili Interactive
    Image attribution tooltip

    Akili cuts 40% of workforce, plans shift to non-prescription model

    The digital therapeutics company expects to extend its cash runway into 2025 with the changes.

    By Elise Reuter • Sept. 13, 2023
  • A podium showing the logo for the Centers for Disease Control and Prevention is seen.
    Image attribution tooltip
    Kevin C. Cox via Getty Images
    Image attribution tooltip

    CDC endorses new COVID boosters as focus turns to rollout

    This fall will now feature vaccination campaigns for COVID-19, influenza and respiratory syncytial virus.

    By • Sept. 13, 2023
  • Explore the Trendline➔
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Commercialization

    New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

    By BioPharma Dive staff
  • Ocean waves
    Image attribution tooltip
    Permission granted by LukaszDesign
    Image attribution tooltip
    Sponsored by Alexander Group

    Do not miss the return to growth

    The signals of a return to growth are emerging. As commercial leaders gear up for 2024 planning, they must prepare to fight for resources in a budget constrained environment.

    By Alexander Group • Sept. 5, 2023
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.
    Image attribution tooltip

    FTC allows Amgen’s $28B deal for Horizon to go through, with conditions

    The settlement between Amgen and the FTC may reassure those in the industry who feared a more activist regulator would gum up dealmaking.

    By • Sept. 1, 2023
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip

    FTC pulls back on legal challenge to Amgen’s $28B bid for Horizon

    Urged by a judge, the antitrust regulator said it wants to start discussions “regarding the proper resolution of this matter” — a potential prelude to a settlement.

    By • Aug. 28, 2023
  • Corporate logos are seen outside on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca the latest pharma to challenge drug pricing law

    The drugmaker's lawsuit follows similar legal challenges from Merck & Co., Bristol Myers Squibb and Johnson & Johnson, among others. 

    By • Aug. 25, 2023
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    FDA approves Novartis’ copycat of blockbuster Biogen drug

    According to one analyst, the approval was the last hurdle keeping Sandoz’s Tyruko from directly competing in the U.S. market against Biogen’s inflammation-regulating medicine Tysabri.

    By • Updated Aug. 25, 2023
  • Image attribution tooltip
    Boehringer Ingelheim
    Image attribution tooltip

    Boehringer sues to block US drug price program

    The pharma’s suit, which claims Medicare’s new power to negotiate certain drug prices is unconstitutional, comes days before the agency will reveal the first 10 medicines to be included under the plan.

    By • Aug. 22, 2023
  • Amazon Pharmacy
    Image attribution tooltip
    Courtesy of Amazon
    Image attribution tooltip

    Amazon Pharmacy expands insulin manufacturer coupons

    The new coupons include some of the most commonly prescribed diabetes drugs from Eli Lilly, Novo Nordisk and Sanofi.

    By Rebecca Pifer • Aug. 17, 2023
  • Nick Jonas poses in front of a glowing background, wearing a small, round device on his upper arm
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    Dexcom, Abbott ramp up DTC marketing in fight for growing diabetes market

    As insurers cover continuous glucose monitors for more people, device makers are taking a page from the pharma marketing playbook.

    By Elise Reuter • Aug. 17, 2023
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx ALS drug sales tick higher after fast US launch

    In Europe, however, the biotech is appealing a negative decision from regulators that has for now blocked its path to market there.

    By • Aug. 11, 2023
  • The European Union flag.
    Image attribution tooltip
    artJazz via Getty Images
    Image attribution tooltip

    Novartis sickle cell drug’s approval formally revoked by EU regulators

    The company said it would withdraw the drug, Adakveo, from the EU market after the European Commission endorsed an earlier EMA recommendation.

    By • Aug. 4, 2023
  • Packaging for Perrigo's over-the-counter birth control Opill
    Image attribution tooltip
    Courtesy of Perrigo
    Image attribution tooltip
    Q&A

    With OTC birth control approved, access battles have just begun

    Perrigo received the first FDA approval for an over-the-counter birth control pill. Now, its global VP of women’s health says the company is working on the next challenge — affordability.  

    By Karissa Waddick • July 31, 2023
  • An image of Apellis Pharmaceuticals' vision loss drug Syfovre
    Image attribution tooltip
    Courtesy of Apellis Pharmaceuticals
    Image attribution tooltip

    Apellis faces safety doubts for fast-selling eye drug

    At a medical meeting, the company confirmed seven cases of a rare, but severe, side effect have been reported following treatment with its geographic atrophy drug Syfovre.

    By • Updated July 31, 2023
  • An image of Apellis Pharmaceuticals' vision loss drug Syfovre
    Image attribution tooltip
    Courtesy of Apellis Pharmaceuticals
    Image attribution tooltip

    Apellis shares sink on reports of rare side effects with new vision loss drug

    An organization of retinal specialists flagged six cases of severe eye inflammation from commercial use of Syfovre. Apellis says the drug’s safety profile is consistent with testing.

    By • July 17, 2023
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    More convenient form of Roche MS drug succeeds in study

    The under-the-skin formulation of Ocrevus can be administered in 10 minutes, versus a longer period for the current intravenous version.

    By Kristin Jensen • July 13, 2023
  • Boxes of the diabetes drug Ozempic rest on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    EMA expands probe of possible suicide risk to popular weight loss, diabetes drugs

    The European drug regulator says it now has 150 reports of possible cases involving self-injury and suicidal thoughts among people taking GLP-1 medicines like Ozempic.

    By Kristin Jensen • July 12, 2023
  • The European Union flag.
    Image attribution tooltip
    artJazz via Getty Images
    Image attribution tooltip

    Illumina hit by EU with maximum fine for Grail acquisition

    The European Commission called Illumina’s closing of the deal without its approval an “unprecedented” move that undermines its system for regulating the competitive landscape.

    By Susan Kelly • July 12, 2023
  • Contact solution sold by Bausch + Lomb sits on a store shelf.
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Bausch + Lomb bulks up OTC business with J&J deal

    The eye care company has become an active acquirer under new CEO Brent Saunders, buying an eye drop product line one week after purchasing several medicines from Novartis.

    By • July 6, 2023
  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical
    Image attribution tooltip

    With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy

    The agency granted a long-awaited clearance last Thursday, but unexpected aspects of the hemophilia treatment’s label had some investors worried about its commercial prospects.

    By • June 30, 2023
  • Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx’s ALS drug gets pushback from European regulators

    An EMA committee expressed concern with the main study meant to show Amylyx’s drug is safe and effective. The company now plans to ask for a re-examination of its approval application.

    By • June 23, 2023
  • former Illumina CEO Francis deSOuza
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    As Illumina’s deSouza departs, will Grail go next?

    The CEO’s resignation signals a change of direction, as anti-trust regulators order Illumina to divest the liquid biopsy unit.

    By Susan Kelly • June 12, 2023
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Bayer launches precision health unit in latest digital health venture

    The pharma company said it will work with startups and other digital health companies as it builds out the consumer-focused business unit.

    By Emily Olsen • June 1, 2023
  • Two mature smiling doctors having discussion about patient diagnosis, holding digital tablet.
    Image attribution tooltip

    Ground Picture/Shutterstock.com

    Image attribution tooltip
    Sponsored by Veeva

    2023 Veeva trends in HCP omnichannel engagement report

    Boost campaign effectiveness by 23% by synchronizing sales and marketing.

    May 30, 2023
  • Rep. Comer sits in front of a poster outlining the cost differences between a drug dispensed at Cost Plus Drugs versus CVS.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Dive
    Image attribution tooltip

    House lawmakers, PBM lobby spar over committee hearing

    At the latest congressional inquiry into pharmacy benefit managers, lawmakers argued the middlemen profit at the expense of patients and taxpayers.

    By Rebecca Pifer • May 25, 2023